- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06609239
Évaluation de l'innocuité et de l'efficacité à long terme de Lunsekimig (SAR443765) chez les participants adultes souffrant d'asthme modéré à sévère. (AIRPHRODITE)
Une étude d'extension ouverte pour évaluer l'innocuité et l'efficacité à long terme de la Lunsekimig sous-cutanée chez les participants adultes souffrant d'asthme modéré à sévère ayant participé à l'étude DRI16762
This is a phase 2, open-label extension study to evaluate the long-term safety and efficacy of lunsekimig in adult participants with asthma who have previously completed the parent studies. After completion of the parent study, eligible participants will be offered the opportunity to participate in the long-term extension (LTE) study with lunsekimig.
The study duration will be up to 148 weeks with a treatment duration being up to 144 weeks.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- Phase 2
Contacts et emplacements
Lieux d'étude
-
-
-
Benoni, Afrique du Sud, 1500
- Investigational Site Number : 7100004
-
Benoni, Afrique du Sud, 1500
- Investigational Site Number : 7100005
-
Cape Town, Afrique du Sud, 7530
- Investigational Site Number : 7100003
-
Cape Town, Afrique du Sud, 7700
- Investigational Site Number : 7100002
-
Durban, Afrique du Sud, 4001
- Investigational Site Number : 7100001
-
Pretoria, Afrique du Sud, 0157
- Investigational Site Number : 7100006
-
-
-
-
-
Leipzig, Allemagne, 04347
- Investigational Site Number : 2760001
-
Mainz, Allemagne, 55128
- Investigational Site Number : 2760005
-
-
-
-
-
Buenos Aires, Argentine, 1121
- Investigational Site Number : 0320005
-
Buenos Aires, Argentine, 1414
- Investigational Site Number : 0320004
-
Buenos Aires, Argentine, 1122
- Investigational Site Number : 0320012
-
Buenos Aires, Argentine, 1425
- Investigational Site Number : 0320011
-
Mendoza, Argentine, 5500
- Investigational Site Number : 0320009
-
Mendoza, Argentine, 5500
- Investigational Site Number : 0320015
-
Santa Fe, Argentine, 3000
- Investigational Site Number : 0320010
-
-
Buenos Aires
-
Berazategui, Buenos Aires, Argentine, 1886
- Investigational Site Number : 0320007
-
La Plata, Buenos Aires, Buenos Aires, Argentine, B1904CUL
- Investigational Site Number : 0320003
-
Lobos, Buenos Aires, Argentine, 7240
- Investigational Site Number : 0320013
-
-
Santa Fe Province
-
Rosario, Santa Fe Province, Argentine, 2000
- Investigational Site Number : 0320002
-
Rosario, Santa Fe Province, Argentine, 2000
- Investigational Site Number : 0320006
-
Rosario, Santa Fe Province, Argentine, 2000
- Investigational Site Number : 0320020
-
-
Tucumán Province
-
San Miguel de Tucumán, Tucumán Province, Argentine, 4000
- Investigational Site Number : 0320008
-
-
-
-
-
Mechelen, Belgique, 2800
- Investigational Site Number : 0560002
-
-
-
-
-
Rio de Janeiro, Brésil, 22241-180
- CCBR / IBPClin - Instituto Brasil de Pesquisa Clínica- Site Number : 0760006
-
São Paulo, Brésil, 05403-000
- Incor - Instituto do Coracao- Site Number : 0760011
-
-
Estado de Bahia
-
Salvador, Estado de Bahia, Brésil, 40060-330
- Associacao Proar- Site Number : 0760003
-
-
Goiás
-
Goiânia, Goiás, Brésil, 74605-020
- Universidade Federal de Goias- Site Number : 0760007
-
-
Paraná
-
Curitiba, Paraná, Brésil, 80030-110
- CETI - Centro de Estudos em Terapias Inovadoras- Site Number : 0760002
-
-
Pernambuco
-
Recife, Pernambuco, Brésil, 50070-550
- Instituto de Medicina Integral Professor Fernando Figueira- Site Number : 0760009
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Brésil, 90610-000
- Hospital São Lucas da PUCRS - Porto Alegre - Avenida Ipiranga- Site Number : 0760001
-
-
Santa Catarina
-
Blumenau, Santa Catarina, Brésil, 89030-101
- Hospital Dia do Pulmão- Site Number : 0760005
-
-
-
-
Ontario
-
Ajax, Ontario, Canada, L1S 2J5
- Investigational Site Number : 1240013
-
Hamilton, Ontario, Canada, L8N 4A6
- Investigational Site Number : 1240003
-
-
Quebec
-
Sherbrooke, Quebec, Canada, J1H 5N4
- Investigational Site Number : 1240004
-
Trois-Rivières, Quebec, Canada, G8T 7A1
- Investigational Site Number : 1240001
-
-
-
-
Biobio
-
Concepción, Biobio, Chili, 4070094
- Investigational Site Number : 1520013
-
-
Maule Region
-
Talca, Maule Region, Chili, 3465584
- Investigational Site Number : 1520001
-
-
Reg Metropolitana de Santiago
-
Recoleta, Reg Metropolitana de Santiago, Chili, 8420000
- Investigational Site Number : 1520015
-
Santiago, Reg Metropolitana de Santiago, Chili, 7500587
- Investigational Site Number : 1520006
-
Santiago, Reg Metropolitana de Santiago, Chili, 7500692
- Investigational Site Number : 1520005
-
Santiago, Reg Metropolitana de Santiago, Chili, 7500698
- Investigational Site Number : 1520004
-
Santiago, Reg Metropolitana de Santiago, Chili, 7750495
- Investigational Site Number : 1520002
-
-
Valparaiso
-
Quillota, Valparaiso, Chili, 2260877
- Investigational Site Number : 1520008
-
Viña del Mar, Valparaiso, Chili, 2531172
- Investigational Site Number : 1520011
-
Viña del Mar, Valparaiso, Chili, 2540364
- Investigational Site Number : 1520012
-
-
-
-
-
Beijing, Chine, 100144
- Investigational Site Number : 1560011
-
Changchun, Chine, 130021
- Investigational Site Number : 1560010
-
Changsha, Chine, 410015
- Investigational Site Number : 1560017
-
Chengde, Chine, 067020
- Investigational Site Number : 1560021
-
Guangzhou, Chine, 510150
- Investigational Site Number : 1560009
-
Guangzhou, Chine, 510000
- Investigational Site Number : 1560053
-
Guangzhou, Chine, 510163
- Investigational Site Number : 1560001
-
Guiyang, Chine, 550002
- Investigational Site Number : 1560037
-
Hefei, Chine, 230032
- Investigational Site Number : 1560006
-
Hohhot, Chine, 010050
- Investigational Site Number : 1560014
-
Lanzhou, Chine, 730000
- Investigational Site Number : 1560030
-
Nanchang, Chine, 330006
- Investigational Site Number : 1560007
-
Pingxiang, Chine, 337055
- Investigational Site Number : 1560002
-
Shanghai, Chine, 200433
- Investigational Site Number : 1560013
-
Shenyang, Chine, 110004
- Investigational Site Number : 1560015
-
Taiyuan, Chine, 030001
- Investigational Site Number : 1560057
-
Tianjin, Chine, 300211
- Investigational Site Number : 1560055
-
Wenzhou, Chine, 325027
- Investigational Site Number : 1560005
-
Wuhan, Chine, 430030
- Investigational Site Number : 1560003
-
Wuhan, Chine, 430030
- Investigational Site Number : 1560022
-
Xuzhou, Chine, 221006
- Investigational Site Number : 1560004
-
Yangzhou, Chine, 225000
- Investigational Site Number : 1560016
-
Zhanjiang, Chine, 524004
- Investigational Site Number : 1560012
-
-
-
-
Seoul-teukbyeolsi
-
Seoul, Seoul-teukbyeolsi, Corée du Sud, 03722
- Investigational Site Number : 4100001
-
Seoul, Seoul-teukbyeolsi, Corée du Sud, 03080
- Investigational Site Number : 4100002
-
Seoul, Seoul-teukbyeolsi, Corée du Sud, 05030
- Investigational Site Number : 4100004
-
Seoul, Seoul-teukbyeolsi, Corée du Sud, 05505
- Investigational Site Number : 4100006
-
Seoul, Seoul-teukbyeolsi, Corée du Sud, 06351
- Investigational Site Number : 4100005
-
-
-
-
-
Madrid, Espagne, 28007
- Investigational Site Number : 7240008
-
-
Catalunya [Cataluña]
-
Barcelona, Catalunya [Cataluña], Espagne, 08017
- Investigational Site Number : 7240009
-
-
Madrid, Comunidad de
-
Chamberí, Madrid, Comunidad de, Espagne, 28010
- Investigational Site Number : 7240011
-
-
-
-
-
Mosonmagyaróvár, Hongrie, 9200
- Investigational Site Number : 3480004
-
-
-
-
-
Calicut, Inde, 673008
- Investigational Site Number : 3560007
-
Hyderabad, Inde, 500084
- Investigational Site Number : 3560009
-
Kanpur, Inde, 208001
- Investigational Site Number : 3560008
-
Nagpur, Inde, 441203
- Investigational Site Number : 3560001
-
Pune, Inde, 411057
- Investigational Site Number : 3560004
-
-
-
-
-
Ashkelon, Israël, 7830604
- Investigational Site Number : 3760006
-
Haifa, Israël, 3104802
- Investigational Site Number : 3760001
-
Haifa, Israël, 3436212
- Investigational Site Number : 3760008
-
Jerusalem, Israël, 9103102
- Investigational Site Number : 3760003
-
Jerusalem, Israël, 9112001
- Investigational Site Number : 3760002
-
Petah Tikva, Israël, 4941492
- Investigational Site Number : 3760010
-
Rehovot, Israël, 7610001
- Investigational Site Number : 3760004
-
Tel Aviv, Israël, 6423906
- Investigational Site Number : 3760007
-
-
-
-
Roma
-
Rome, Roma, Italie, 00168
- Investigational Site Number : 3800010
-
-
-
-
-
Fukushima, Japon, 960-1295
- Investigational Site Number : 3920008
-
Kyoto, Japon, 610-0113
- Investigational Site Number : 3920006
-
Kyoto, Japon, 612-8555
- Investigational Site Number : 3920009
-
Miyazaki, Japon, 889-1692
- Investigational Site Number : 3920012
-
-
Kagawa-ken
-
Sakaidechō, Kagawa-ken, Japon, 762-8550
- Investigational Site Number : 3920002
-
-
Tokyo
-
Chūō, Tokyo, Japon, 104-0031
- Investigational Site Number : 3920011
-
-
Yamaguchi
-
Ube, Yamaguchi, Japon, 755-8505
- Investigational Site Number : 3920005
-
-
-
-
-
Chihuahua City, Mexique, 31000
- Investigational Site Number : 4840002
-
Durango, Mexique, 34000
- Investigational Site Number : 4840003
-
Veracruz, Mexique, 91900
- Investigational Site Number : 4840008
-
-
Nuevo León
-
Monterrey, Nuevo León, Mexique, 66465
- Investigational Site Number : 4840004
-
-
Querétaro
-
San Juan del Río, Querétaro, Mexique, 76800
- Investigational Site Number : 4840005
-
-
Yucatán
-
Mérida, Yucatán, Mexique, 97070
- Investigational Site Number : 4840007
-
-
-
-
Greater Poland Voivodeship
-
Poznan, Greater Poland Voivodeship, Pologne, 60-693
- Investigational Site Number : 6160001
-
-
Świętokrzyskie Voivodeship
-
Chęciny, Świętokrzyskie Voivodeship, Pologne, 26-060
- Investigational Site Number : 6160004
-
-
-
-
-
Bradford, Royaume-Uni, BD9 6DA
- Investigational Site Number : 8260008
-
-
Cambridgeshire
-
Cambridge, Cambridgeshire, Royaume-Uni, CB2 2QQ
- Investigational Site Number : 8260001
-
-
Glasgow City
-
Glasgow, Glasgow City, Royaume-Uni, G12 0YN
- Investigational Site Number : 8260004
-
-
London, City of
-
London, London, City of, Royaume-Uni, W1G 8HU
- Investigational Site Number : 8260011
-
-
Surrey
-
Chertsey, Surrey, Royaume-Uni, KT16 0PZ
- Investigational Site Number : 8260005
-
-
-
-
-
Taipei, Taïwan, 110
- Investigational Site Number : 1580003
-
-
-
-
-
Bursa, Turquie (Türkiye), 16059
- Investigational Site Number : 7920006
-
Istanbul, Turquie (Türkiye), 34098
- Investigational Site Number : 7920002
-
Istanbul, Turquie (Türkiye), 34854
- Investigational Site Number : 7920003
-
Kayseri, Turquie (Türkiye), 38039
- Investigational Site Number : 7920007
-
Kirikkale, Turquie (Türkiye), 71100
- Investigational Site Number : 7920008
-
Mersin, Turquie (Türkiye), 33070
- Investigational Site Number : 7920001
-
İzmit, Turquie (Türkiye), 41001
- Investigational Site Number : 7920005
-
-
-
-
Arizona
-
Chandler, Arizona, États-Unis, 85224
- Chandler Clinical Research Trials- Site Number : 8400075
-
Tucson, Arizona, États-Unis, 85712
- Tucson Clinical Research Institute- Site Number : 8400085
-
-
Colorado
-
Aurora, Colorado, États-Unis, 80014
- Allianz Research Institute - Aurora- Site Number : 8400026
-
Wheat Ridge, Colorado, États-Unis, 80033
- Western States Clinical Research- Site Number : 8400014
-
-
Florida
-
Boynton Beach, Florida, États-Unis, 33435
- Helix Biomedics- Site Number : 8400114
-
Cutler Bay, Florida, États-Unis, 33157
- Beautiful Minds Clinical Research Center- Site Number : 8400049
-
Hialeah, Florida, États-Unis, 33010
- Qway Research - Hialeah- Site Number : 8400015
-
Kissimmee, Florida, États-Unis, 34744
- Ilumina Medical Research- Site Number : 8400095
-
Miami, Florida, États-Unis, 33184
- High Quality Research- Site Number : 8400039
-
Miami, Florida, États-Unis, 33186
- Innovations Biotech- Site Number : 8400040
-
Miami, Florida, États-Unis, 33186
- New Access Medical Center- Site Number : 8400043
-
Miami, Florida, États-Unis, 33135
- Clintex Research Group - Miami - Southwest 27th Avenue- Site Number : 8400048
-
Miami Lakes, Florida, États-Unis, 33014
- Deluxe Health Center- Site Number : 8400045
-
Pembroke Pines, Florida, États-Unis, 33025
- Tellabio International Research Services- Site Number : 8400083
-
Pembroke Pines, Florida, États-Unis, 33029
- Alfa Medical Research LLC- Site Number : 8400146
-
Pensacola, Florida, États-Unis, 32503
- Avanza Medical Research Center- Site Number : 8400135
-
Sarasota, Florida, États-Unis, 34239
- Windom Allergy, Asthma and Sinus Specialists- Site Number : 8400019
-
-
Georgia
-
Cordele, Georgia, États-Unis, 31015
- Private Practice - Dr. David Kavtaradze- Site Number : 8400081
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02115
- Brigham & Women's Hospital- Site Number : 8400034
-
-
Michigan
-
Ann Arbor, Michigan, États-Unis, 48109
- University of Michigan Health System - Ann Arbor- Site Number : 8400004
-
-
Missouri
-
St Louis, Missouri, États-Unis, 63141
- Midwest Clinical Research Center - St. Louis- Site Number : 8400006
-
-
North Carolina
-
Charlotte, North Carolina, États-Unis, 28287
- Tryon Medical Partners - Charlotte - Piedmont Row Drive South- Site Number : 8400029
-
-
Ohio
-
Toledo, Ohio, États-Unis, 43617
- Asthma & Allergy Center - Toledo- Site Number : 8400017
-
-
Oklahoma
-
Edmond, Oklahoma, États-Unis, 73034
- OK Clinical Research- Site Number : 8400021
-
-
Pennsylvania
-
DuBois, Pennsylvania, États-Unis, 15801
- Clinical Research Associates of Central Pennsylvania- Site Number : 8400116
-
Pittsburgh, Pennsylvania, États-Unis, 15241
- Allergy & Clinical Immunology Associates Pittsburgh- Site Number : 8400007
-
-
Texas
-
Austin, Texas, États-Unis, 78759
- Orion Clinical Research- Site Number : 8400001
-
Boerne, Texas, États-Unis, 78006
- South Texas Medical Research Institute - TTS Research- Site Number : 8400010
-
Dallas, Texas, États-Unis, 75246
- Baylor University Medical Center- Site Number : 8400002
-
El Paso, Texas, États-Unis, 79903
- Western Sky Medical Research- Site Number : 8400023
-
McKinney, Texas, États-Unis, 75069
- Metroplex Pulmonary and Sleep Center- Site Number : 8400022
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
-
Participants who completed the treatment period of Study DRI16762 or ACT18301, including the EOT visit, as per protocol
-
Participants with stable background therapy with moderate or high-dose ICS in combination with the following controller medications, as maintained during the respective parent study in which they have participated:
- For Study DRI16762: At least 1 and no more than 2 additional controllers (eg, LABA, LAMA, LTRA, or methylxanthines), with or without oral prednisone
- For Study ACT18301: LABA with or without LTRA
-
Participants who are able and willing to participate in the open-label extension study, and to comply with requested study visits and procedures
-
Contraception for male and female participants during the study intervention period and during 8 weeks following the last administration of study intervention. And:
For female participants:
- incapable of becoming pregnant, or
- not pregnant or breast feeding
- no eggs donation or cryopreserving eggs
For male participants:
-- No sperm donation or cryopreserving sperm
- Capable of giving signed informed consent
Exclusion Criteria:
Participants are excluded from the study if any of the following criteria apply:
- Participant who developed a new medical condition or a change in status of an established medical condition or requires a new treatment or medication prior to enrollment that, per Investigator's medical judgement would adversely affect participation of the participant in this study or would require permanent lunsekimig discontinuation, or participants potentially at risk of noncompliance to study procedures
- Participant who was diagnosed with a new pulmonary disease which may impair lung function
- Current smoker or active vaping of any products and/or marijuana smoking
- Prescription drug or substance abuse, including alcohol, considered significant by the Investigator
- History of hypersensitivity or allergy to lunsekimig or to any of the excipients used in the presentation or in preparation for administration of lunsekimig, or other allergy that, in the opinion of the Investigator, contraindicates participation in the study
- Participants who are receiving prohibited concomitant medications
- Participants who, during their participation in the parent study, developed an AE or an SAE deemed related to lunsekimig, which in the opinion of the Investigator could indicate that continued treatment with lunsekimig may present an unreasonable risk for the participant
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Lunsekimig
Participants will receive subcutaneous injection of lunsekimig according to established dosing interval |
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Exposure-adjusted incidence rate of treatment-emergent adverse event (TEAE), including adverse events of special interest (AESI), and serious adverse event (SAE)
Délai: From study baseline to week 148
|
Exposure-adjusted incidence rate is defined as the number of patients with at least one specific treatment emergent adverse event in question per 100 patients taking the treatment for 1 year. |
From study baseline to week 148
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Annualized rate of asthma exacerbation events
Délai: From study baseline to weeks 48, 96 and 144
|
From study baseline to weeks 48, 96 and 144
|
|
|
Change from parent study baseline in pre-bronchodilator (BD) forced expiratory volume in 1 second (FEV1)
Délai: From parent study baseline to weeks 48, 96 and 144
|
From parent study baseline to weeks 48, 96 and 144
|
|
|
Serum lunsekimig concentrations
Délai: From study baseline to week 144
|
From study baseline to week 144
|
|
|
Incidence and titer of anti-drug antibodies (ADA) against lunsekimig
Délai: From study baseline to week 144
|
From study baseline to week 144
|
|
|
Change from parent study baseline in Asthma Control Questionnaire5 (ACQ-5) score
Délai: From parent study baseline to weeks 48, 96 and 144
|
The ACQ-5 is a questionnaire that measures the adequacy of asthma control and any changes in asthma control that may occur spontaneously or as a result of treatment. The ACQ-5 has five questions on the asthma symptoms and patients are asked to recall how their asthma has been during the previous week and to respond on a 7-point scale for each question (0 = no impairment, 6 = maximum impairment). The ACQ-5 score is the mean of the 5 questions and, therefore, between 0 (totally controlled) and 6 (severely uncontrolled). A high score indicates low asthma control. |
From parent study baseline to weeks 48, 96 and 144
|
|
Proportion of participants with ≥0.5-point reduction in each ACQ-5 score as compared to parent study baseline score
Délai: From parent study baseline to weeks 48, 96 and 144
|
Defined as ACQ-5 responder analysis |
From parent study baseline to weeks 48, 96 and 144
|
|
Change from parent study baseline in Asthma Quality of Life Questionnaire Standardized Activites for 12 years and older (AQLQ[S] +12) domain and total scores
Délai: From parent study baseline to weeks 48, 96 and 144
|
The AQLQ(S) + 12 was designed as a self-administered patient reported outcome to measure the functional impairments that are most troublesome to adolescents and adults ≥12 years of age as a result of their asthma. The instrument is comprised of 32 items, each rated on a 7-point Likert scales from 1 to 7. Higher scores indicate better quality of life. |
From parent study baseline to weeks 48, 96 and 144
|
Collaborateurs et enquêteurs
Parrainer
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- LTS17231
- 2025-522896-27 (Identificateur de registre: CTIS)
- U1111-1303-3645 (Identificateur de registre: ICTRP)
- 2025 (Subvention/contrat des NIH des États-Unis)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .